Literature DB >> 24662175

UK Renal Registry 16th annual report: chapter 11 blood pressure profile of prevalent patients receiving renal replacement therapy in 2012: national and centre-specific analyses.

Anirudh Rao1, David Pitcher, Ken Farrington.   

Abstract

INTRODUCTION: There continues to be uncertainty in the literature about which blood pressure (BP) recordings in which time period associate best with long-term patient outcomes and therefore optimal target ranges.
METHODS: Patients receiving renal replacement therapy (RRT) on 31st December 2012 with a BP reading in either the fourth or third quarter of 2012 were included. Summary statistics were calculated for each renal centre and country.
RESULTS: Data completeness for BP measurements submitted to the UK Renal Registry (UKRR) for all modalities were improved from previous years: it was better for haemodialysis (HD) patients (75% for pre-HD measurements) than for peritoneal dialysis (PD) patients (51%) or transplant recipients (41%). In 2012, the median pre- and post-HD systolic blood pressures (SBPs) were 140 mmHg and 128 mmHg respectively. The median SBP of patients on PD was 137 mmHg. Transplant recipients had a median SBP of 134 mmHg. Median diastolic blood pressures (DBPs) were 71 mmHg (pre-HD), 67 mmHg (post-HD), 78 mmHg (PD) and 79 mmHg (transplant). Only 26% of PD patients achieved the Renal Association guideline of SBP <130 mmHg and DBP <80 mmHg. Amongst transplant patients, 27% achieved the Renal Association guideline of SBP <130 mmHg and DBP <80 mmHg.
CONCLUSION: In 2012 there continued to be significant variation in the achievement of BP standards between UK renal centres.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 24662175     DOI: 10.1159/000360030

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  1 in total

1.  The effect of dietary salt on blood pressure in individuals receiving chronic dialysis: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Nicholas I Cole; Pauline A Swift; Feng J He; Graham A MacGregor; Rebecca J Suckling
Journal:  J Hum Hypertens       Date:  2018-11-09       Impact factor: 3.012

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.